Introduction
Sunday 29 September 2019
ESMO 2019, Barcelona

George Pentheroudakis
DISCLOSURE INFORMATION

George Pentheroudakis

Personal financial interests (advisory services, speaking engagements): Amgen, Merck, Astra Zeneca, Roche, BMS, MSD, Lilly

Research support: Boehringer, Amgen, Merck, Astra Zeneca, Roche, Enorasis, BMS, Lilly

Institutional financial support for clinical trial research: Boehringer, Merck, Amgen, Astra Zeneca, Roche, Lilly, Abbvie, Debiopharm, Ipsen.

Non remunerated posts: Board, Society for Study of Clonal Heterogeneity of Neoplasia
ESMO Guidelines Products

ESMO Clinical Practice Guidelines

- Evidence-based, multidisciplinary guidelines
- Reviewed by independent experts and patients (ECPC)
- The standard for best practice
- Available on the ESMO and OncologyPRO websites: esmo.org / oncologypro.org
- Published in Annals of Oncology

Number of ESMO CPGs

<table>
<thead>
<tr>
<th>Year</th>
<th>CPGs</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>34</td>
</tr>
<tr>
<td>2006</td>
<td>39</td>
</tr>
<tr>
<td>2007</td>
<td>47</td>
</tr>
<tr>
<td>2008</td>
<td>54</td>
</tr>
<tr>
<td>2009</td>
<td>54</td>
</tr>
<tr>
<td>2010</td>
<td>55</td>
</tr>
<tr>
<td>2011</td>
<td>55</td>
</tr>
<tr>
<td>2012</td>
<td>57</td>
</tr>
<tr>
<td>2013</td>
<td>59</td>
</tr>
<tr>
<td>2014</td>
<td>64</td>
</tr>
<tr>
<td>2015</td>
<td>70</td>
</tr>
<tr>
<td>2016</td>
<td>72</td>
</tr>
<tr>
<td>2017</td>
<td>75</td>
</tr>
<tr>
<td>2018</td>
<td>78</td>
</tr>
</tbody>
</table>
2019: ESMO Clinical Practice Guidelines

6 New and updated titles:
• PAGA of ESMO NSCLC Guideline
• Renal Cell Carcinoma
• Early Breast Cancer
• Hereditary Gastrointestinal Cancers
• Non-small cell Metastatic Lung Cancer
• Thyroid cancer

5 Titles submitted to Annals of Oncology:
• Cutaneous Melanoma
• Marginal Zone Lymphomas
• PAGA of ESMO LA NSCLC Guideline
• PAGA of ESMO Early Breast Cancer Guideline
• PAGA of ESMO Hepatoma Guideline
ESMO Guidelines Products

eUpdates: www.esmo.org/Guidelines/Guidelines-News

8 eUpdates:
- Grading and Treatment Recommendations for Gastric Cancer
- Updated Treatment Recommendations for Cancer of the Prostate
- Updated Treatment Recommendation and Algorithm for Soft Tissue and Visceral Sarcomas
- Grading and Treatment Recommendations for Cancer of the Pancreas
- Grading and Treatment Recommendations for Hepatocellular Carcinoma
- Updated Treatment Algorithm for Hepatocellular Carcinoma
- Bladder Cancer Treatment Recommendations
- Early Colon Cancer Treatment Recommendations
THE LIVING GUIDELINE: A PILOT

Electronic updates are fully integrated into the parent Guideline

Newly published (18/SEPT/2019):

- Metastatic non-small cell lung cancer
- Both the updated (2019) and original (Annals 2018) versions are available on the ESMO website

ESMO Consensus Guidelines

• Derived from Consensus Conferences
• Pre-selected controversial questions addressed by multidisciplinary experts on specific tumour types

Recently published:
• ESMO–ESGO Consensus Conference Recommendations on Ovarian Cancer

Submitted to Ann Oncol:
• EAU–ESMO consensus statements on the management of advanced and variant bladder cancer
• Management of Cardiac Disease in Cancer Patients

Manuscript in development:
• ESMO Melanoma Consensus Conference, September 2019
ESMO Guidelines Slide Sets: 4

- Set of 15-25 slides for each CPG title
- Downloadable in PDF and PowerPoint from esmo.org
- Concise: algorithms and tables with key recommendations
Since 2016 there were over 1 million unique page views* of ESMO Guidelines pages on the ESMO.org website each year.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total for guidelines</td>
<td>89,530</td>
<td>100,738</td>
<td>394,889</td>
<td>738,260</td>
<td>893,000</td>
<td>1,052,185</td>
<td>1,377,993</td>
<td>1,582,195</td>
<td>1,151,580 (to end Aug)</td>
</tr>
</tbody>
</table>
WHAT’S NEW AT ESMO 2019?

8 Pocket Guidelines titles distributed in the Society Village & Exhibition Hall
(refer to the flyer in your delegate bag)

• Breast Cancer
• Endocrine & NETs
• Leukaemia & Myeloma
• Lower Gastrointestinal Cancer

• Lung & Chest Tumours
• Supportive Care
• Upper Gastrointestinal Cancer
• Urogenital Tumours (2018)
ESMO Guidelines Products

- Guidelines Mobile and WEB App

Interactive App versions:
- Lung & Chest Tumours
- Upper Gastrointestinal cancers
- Lower gastrointestinal cancers
- Urogenital cancer
- Supportive care
- Lymphomas
- Breast cancer
- Leukaemia & Myeloma

PDF versions:
- Gynaecological Malignancies
- Melanoma
- Sarcoma & GIST
- Bone Health
- Head & Neck cancer
ESMO Patient Guides

• Patient-education guides produced by ESMO
• Designed to assist patients, their relatives and caregivers to understand cancer and evaluate treatment options
• esmo.org, downloadable in PDF format
DON’T FORGET TO PICK UP YOUR COPIES

Delegate bag flyer, specifying where to collect each title @ ESMO 2019

- ESMO Pocket Guidelines
- Patient Guides series
ESMO Clinical Practice Guidelines sessions

Sunday 29 September 2019

Session 1: 09h45-11h45
- Stage III ovarian cancer, BRCA wild type germline and somatic, platinum-sensitive relapse and molecular profiling (Irina Tsibulak, Mansoor Raza Mirza)
- Metastatic non-small cell lung cancer: Immunotherapy (Roberto Ferrara, Noemi Reguart)
- Metastatic Renal Cancer (Ricardo Pereira, Tom Powles)
- Stage III colorectal cancer: duration of therapy, molecular profiling (George Zarkavelis, Guillem Argiles)

Session 2: 14h45-16h45
- Localised melanoma resected: adjuvant therapy followed by systemic relapse (Rebecca Lee, Olivier Michielin)
- Fatigue in cancer (Juliane Brandt, Fausto Roila)
- Advanced Hepatoma: Sequence of therapies (Daire Hanna, Arndt Vogel)
- Urothelial cancer: bladder-preserving strategies followed by systemic relapse (Bernadett Szabados, Shahrokh Shariat)

Webcasts available within 48 hours! www.oncologypro.org